Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes

The Wall Street JournalView source article

Part of story

Moderna posts first quarterly profit in two years, raises revenue forecast

Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.

Nov 6, 20265 sourcesCOVID-19 vaccines Cancer & Oncology Pharmaceutical Industry Clinical trials Cancer immunotherapy MRNA vaccine technology FDA drug approval Corporate earnings

Moderna posts first quarterly profit in two years, raises revenue forecast

Other sources for this story

Financial Times

Moderna swings to profit as momentum for cancer vaccine builds

Reuters

Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas | Reuters

Endpoints

Moderna ekes out a profit, its first in two years

Bloomberg

Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes

Part of story

Moderna posts first quarterly profit in two years, raises revenue forecast

Other sources for this story

Moderna swings to profit as momentum for cancer vaccine builds

Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas | Reuters

Moderna ekes out a profit, its first in two years

Moderna Boosts Revenue Guidance on Covid Vaccine Sales

Moderna Swings to Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes

Part of story

Moderna posts first quarterly profit in two years, raises revenue forecast

Other sources for this story

Moderna swings to profit as momentum for cancer vaccine builds

Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas | Reuters

Moderna ekes out a profit, its first in two years

Moderna Boosts Revenue Guidance on Covid Vaccine Sales